BAM
ACXP icon

Belpointe Asset Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Belpointe Asset Management’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-150
Closed -$10.4K – 644
2023
Q1 		$10.4K Hold
150
– – ﹤0.01% 2698
2022
Q4 		$11.9K Buy
+150
New +$9.87K ﹤0.01% 2520

Other funds holding ACXP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OGC
One68 Global Capital New York $30.9M AUM
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Belpointe Asset Management's ACXP Position: Q2 2023 in Review

Belpointe Asset Management sold out of Acurx Pharmaceuticals (ACXP) in Q2 2023, closing a stake of 150 shares — an estimated $10.4K sold.

Belpointe Asset Management first reported a position in ACXP in Q4 2022 and held it in 2 quarters. The position peaked at $11.9K in Q4 2022. 13 funds tracked by Wall St. Rank hold ACXP as of Q2 2023.

  • Belpointe Asset Management reported no remaining Acurx Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 150 Acurx Pharmaceuticals shares in Q2 2023, an estimated $10.4K.
  • Belpointe Asset Management first reported a position in Acurx Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Acurx Pharmaceuticals position peaked at $11.9K in Q4 2022.
  • 13 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.